Circular RNA‐based neoantigen vaccine for hepatocellular carcinoma immunotherapy DOI Creative Commons
Fei Wang,

Cai Guang,

Yingchao Wang

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(8)

Published: July 29, 2024

Abstract mRNA vaccines are regarded as a highly promising avenue for next‐generation cancer therapy. Nevertheless, the intricacy of production, inherent instability, and low expression persistence linear significantly restrict their extensive utilization. Circular RNAs (circRNAs) offer novel solution to these limitations due efficient protein ability, which can be rapidly generated in vitro without need extra modifications. Here, we present neoantigen vaccine based on circRNA that induces potent anti‐tumor immune response by expressing hepatocellular carcinoma‐specific tumor neoantigens. By cyclizing linearRNA molecules, were able enhance stability RNA form stable molecules with capacity sustained expression. We confirmed neoantigen‐encoded promote dendritic cell (DC) activation DC‐induced T‐cell vitro, thereby enhancing killing cells. Encapsulating within lipid nanoparticles vivo has enabled creation platform. This platform demonstrates superior treatment prevention various murine models, eliciting robust response. Our offers new options application prospects immunotherapy solid tumors.

Language: Английский

Recent progress in mRNA cancer vaccines DOI Creative Commons

Ruhui Yao,

C. Xie, Xiaojun Xia

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Jan. 28, 2024

The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application personalized antigens, structural optimization mRNA, alternative RNA-based vectors efficient targeted delivery vectors. Clinical trials are currently underway for various that encode tumor-associated antigens (TAAs), tumor-specific (TSAs), or immunomodulators. In this paper, we summarize mRNA emergence expression in vaccines. We begin by reviewing advancement utilization state-of-the-art lipid nanoparticles (LNPs), followed presenting primary classifications clinical applications Collectively, emerging as a central focus immunotherapy, offering potential to address multiple treatment, either standalone therapies combination with current treatments.

Language: Английский

Citations

39
Therapeutic potential of RNA-enriched extracellular vesicles: The next generation in RNA delivery via biogenic nanoparticles DOI

Muskan Muskan,

Pevindu Abeysinghe,

Riccardo Cecchin

et al.

Molecular Therapy, Journal Year: 2024, Volume and Issue: 32(9), P. 2939 - 2949

Published: Feb. 27, 2024

Language: Английский

Citations

38
Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy DOI Creative Commons
Xueqiang Peng,

Jianjun Fang,

Chuyuan Lou

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(8), P. 3432 - 3456

Published: May 13, 2024

The advent of cancer immunotherapy has imparted a transformative impact on treatment paradigms by harnessing the power immune system. However, challenge practical and precise targeting malignant cells persists. To address this, engineered nanoparticles (NPs) have emerged as promising solution for enhancing targeted drug delivery in immunotherapeutic interventions, owing to their small size, low immunogenicity, ease surface modification. This comprehensive review delves into contemporary research at nexus NP engineering immunotherapy, encompassing an extensive spectrum morphologies strategies tailored toward optimizing tumor augmenting therapeutic effectiveness. Moreover, it underscores mechanisms that NPs leverage bypass numerous obstacles encountered regimens probes combined potential when co-administered with both established novel modalities. Finally, evaluates existing limitations platforms which could shape path future advancements this field.

Language: Английский

Citations

23
Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect DOI Creative Commons
Tianjiao Wang, Youhong Tang,

Yuandong Tao

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 2(1)

Published: Jan. 1, 2024

Abstract Over the two decades, RNA drugs have gradually made their way from bench to bed. Initially, was not an ideal drug since molecules degrade easily and a relatively short half‐life in circulation system. Nevertheless, chemical modification extended of recent years, which makes new star discovery industry. hold many properties that facilitate application as therapeutic drugs. RNAs could fold form complex conformations bind proteins, small molecules, or other nucleic acids, some even catalytic centers. Protein‐encoding are carriers genetic information DNA ribosomes, various types non‐coding cooperate transcription translation through mechanisms. To date, three mainstream therapies drawn widespread attention: (1) messenger encodes proteins vaccine antigens; (2) interfering RNA, microRNA (miRNA), antisense oligonucleotides inhibit activity pathogenic RNAs; (3) aptamers regulate protein activity. Here, we summarized current research perspectives therapies, may provide innovative highlights for cancer therapy.

Language: Английский

Citations

19
IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation DOI Creative Commons
Caitlin M. Tilsed, Barzan A. Sadiq, Tyler E. Papp

et al.

Proceedings of the National Academy of Sciences, Journal Year: 2024, Volume and Issue: 121(13)

Published: March 21, 2024

The use of lipid nanoparticles (LNP) to encapsulate and deliver mRNA has become an important therapeutic advance. In addition vaccines, LNP-mRNA can be used in many other applications. For example, targeting the LNP with anti-CD5 antibodies (CD5/tLNP) allow for efficient delivery payloads T cells express protein. As percentage protein expressing induced by intravenous injection CD5/tLNP is relatively low (4-20%), our goal was find ways increase mRNA-induced translation efficiency. We showed that cell activation using anti-CD3 antibody improved expression after transfection vitro but not vivo. health increased cytokines, therefore, mCherry as a reporter, we found culturing either mouse or human cytokine IL7 significantly delivered both CD4 + CD8 vitro. By pre-treating mice systemic followed tLNP administration, observed Transcriptomic analysis treated revealed enhanced genomic pathways associated translation. Improved translational ability demonstrated showing levels electroporation cultured presence IL7, IL2 IL15. These data show selectively increases cells, this property improve tLNP-delivered

Language: Английский

Citations

18
Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape Without Side Effects DOI Open Access
Serena Omo‐Lamai, Yufei Wang, Manthan N. Patel

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: April 18, 2024

Abstract Lipid nanoparticles (LNPs) have emerged as the dominant platform for RNA delivery, based on their success in COVID-19 vaccines and late-stage clinical studies other indications. However, we others shown that LNPs induce severe inflammation, massively aggravate pre-existing inflammation. Here, using structure-function screening of lipids analyses signaling pathways, elucidate mechanisms LNP-associated inflammation demonstrate solutions. We show LNPs’ hallmark feature, endosomal escape, which is necessary expression, also directly triggers by causing membrane damage. Large, irreparable, holes are recognized cytosolic proteins called galectins, bind to sugars inner then regulate downstream find inhibition galectins abrogates both vitro vivo . rapidly biodegradable ionizable can preferentially create smaller size reparable sorting complex required transport (ESCRT) pathway. Ionizable producing such ESCRT-recruiting produce high expression from cargo mRNA with minimal Finally, routes non-inflammatory LNPs, either galectin or lipids, compatible therapeutic mRNAs ameliorate disease models. without lead exacerbation these In summary, escape induces damage be controlled inhibiting (large hole detectors) ESCRT These strategies should generally safer used treat inflammatory diseases.

Language: Английский

Citations

18
Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model DOI Creative Commons
Carole Fournier, Marion Mercey-Ressejac, Valentin Dérangère

et al.

EBioMedicine, Journal Year: 2025, Volume and Issue: 112, P. 105543 - 105543

Published: Jan. 9, 2025

Language: Английский

Citations

2
Revolutionizing Drug Delivery: The Impact of Advanced Materials Science and Technology on Precision Medicine DOI Creative Commons
Mohamed El‐Tanani, Shakta Mani Satyam, Syed Arman Rabbani

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 375 - 375

Published: March 15, 2025

Recent progress in material science has led to the development of new drug delivery systems that go beyond conventional approaches and offer greater accuracy convenience application therapeutic agents. This review discusses evolutionary role nanocarriers, hydrogels, bioresponsive polymers enhanced release, target accuracy, bioavailability. Oncology, chronic disease management, vaccine are some applications explored this paper show how these materials improve results, counteract multidrug resistance, allow for sustained localized treatments. The also translational barriers bringing advanced into clinical setting, which include issues biocompatibility, scalability, regulatory approval. Methods overcome challenges surface modifications reduce immunogenicity, scalable production methods such as microfluidics, harmonization systems. In addition, convergence artificial intelligence (AI) machine learning (ML) is opening frontiers personalized medicine. These technologies predictive modeling real-time adjustments optimize needs individual patients. use can be applied rare underserved diseases; thus, strategies gene therapy, orphan drugs development, global distribution may hopes millions

Language: Английский

Citations

2
Biomedical applications of nanomaterials in the advancement of nucleic acid therapy: Mechanistic challenges, delivery strategies, and therapeutic applications DOI Open Access
Krishna Yadav, Kantrol Kumar Sahu,

Sucheta

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 241, P. 124582 - 124582

Published: April 26, 2023

Language: Английский

Citations

34
An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations DOI Open Access
Mona Sadat Mirtaleb, Reza Falak, Jalal Heshmatnia

et al.

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 117, P. 109934 - 109934

Published: Feb. 27, 2023

Language: Английский

Citations

28